Notably, we modified the inclusion criteria from the CREDENCE and DAPA-CKD trials to increase the generalizability of our findings to a wider CKD population (ie, stages 1-3) and to investigate the potential class effect of SGLT2 inhibitors with regard to incident anemia. Here, SLC5A2 is linked to chronic kidney disease.